Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-11-27
2011-10-25
Desai, Anand (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C424S489000
Reexamination Certificate
active
08044021
ABSTRACT:
A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.
REFERENCES:
patent: 4643988 (1987-02-01), Segrest et al.
patent: 4925677 (1990-05-01), Feijen
patent: 5202745 (1993-04-01), Sorin et al.
patent: 5291267 (1994-03-01), Sorin et al.
patent: 5321501 (1994-06-01), Swanson et al.
patent: 5365125 (1994-11-01), Goetting et al.
patent: 5459570 (1995-10-01), Swanson et al.
patent: 5465147 (1995-11-01), Swanson
patent: 5700484 (1997-12-01), Chauffard et al.
patent: 5783600 (1998-07-01), Bisgaier et al.
patent: 5874075 (1999-02-01), Collins et al.
patent: 6124273 (2000-09-01), Drohan et al.
patent: 6376464 (2002-04-01), Dasseux et al.
patent: 6506799 (2003-01-01), Dasseux
patent: 6602854 (2003-08-01), Dasseux et al.
patent: 6692466 (2004-02-01), Chow et al.
patent: 6753313 (2004-06-01), Dasseux et al.
patent: 6831105 (2004-12-01), Dasseux
patent: 6844327 (2005-01-01), Dasseux et al.
patent: 6852760 (2005-02-01), Fine et al.
patent: 6878817 (2005-04-01), Lees et al.
patent: 6881860 (2005-04-01), Luchoomun et al.
patent: 6900177 (2005-05-01), Dasseux et al.
patent: 6960648 (2005-11-01), Bonny
patent: 7273469 (2007-09-01), Chan et al.
patent: 2004/0229794 (2004-11-01), Ryan et al.
patent: 2004/0254120 (2004-12-01), Fogelman et al.
patent: 2004/0266671 (2004-12-01), Fogelman et al.
patent: 2005/0118226 (2005-06-01), Kovacs et al.
patent: 2005/0175666 (2005-08-01), Ding
patent: 2005/0176623 (2005-08-01), Wagle
patent: 2005/0202532 (2005-09-01), Bielicki et al.
patent: 2005/0222029 (2005-10-01), Bartel et al.
patent: 2005/0232981 (2005-10-01), Ben-Sasson
patent: 2009/0081293 (2009-03-01), Murase et al.
patent: 2009/0081299 (2009-03-01), Hossainy et al.
patent: WO-9736927 (1997-10-01), None
patent: WO-9916408 (1999-04-01), None
patent: WO-03026492 (2003-04-01), None
patent: WO-03096983 (2003-11-01), None
patent: WO-2005041866 (2005-05-01), None
patent: WO-2006047279 (2006-05-01), None
patent: WO-2006100567 (2006-09-01), None
patent: WO-2006100567 (2006-09-01), None
patent: WO-2008048387 (2008-04-01), None
patent: WO-2008048387 (2008-04-01), None
“Apo A-1 from Human”, NCBI Accession No. P02647; Accessed Jun. 15, 2010, 1-14.
Abbott Cardiovascular Systems, Non final office action dated Apr. 6, 2010 for U.S. Appl. No. 11/858,851.
Abbott Cardiovascular Systems, Final Office Action dated Jun. 17, 2010 for U.S. Appl. No. 11/946,028.
Abbott Cardiovascular Systems, Non-Final Office Action dated Jul. 21, 2010 for U.S. Appl. No. 11/858,862.
Abbott Cardiovascular Systems, International Preliminary Report on Patentability mailed Jun. 10, 2010 for PCT/US2008/012793.
Abbott Cardiovascular Systems, International Preliminary Report on Patentability mailed Jun. 10, 2010 for PCT/US2008/012794.
Abbott Cardiovascular Systems, International Preliminary Report on Patentability mailed Jun. 10, 2010 for PCT/US2008/012767.
Gu, et al., “Apolipoprotein A-1 from Beijing Duck”, NCBI Accession No. AAB30359; Accessed Jun. 15, 2010, 1 page.
Knott, et al., “Apolipoprotein from human”, NCBI Accession No. CAA28583.1; Accessed Jun. 15, 2010, 1 page.
PCT International Search Report (dated Dec. 5, 2009), International Application No. PCT/US2008/012767, International Filing Date—Nov. 14, 2008, (Whole Document).
Ramprasad, Mysore P., et al., “Sustained-Delivery of an ApolipoproteinE-Peptidomimetic Using Multivesicular Liposomes Lowers Serum Cholesterol Levels”, Journal of Controlled Release, Elsevier, Amsterdam, NL, vol. 79, No. 1-3, Feb. 19, 2002, XP004340926, ISSN: 0168-3659, (pp. 207-218).
“Arisaph Reports on Promising Results Presented at AHA: Novel APO A-I Mimetic Peptide Significantly Inhibits Atherosclerosis in Preclinical Animal Study”, News Release, Arisaph Pharmaceuticals, Boston, MA, (Nov. 15, 2005), 2 pages.
Definition of derivative and analog from ://cancerweb.ncl.ac.uk/cgi-bin/omd?query=derivative, (Jul. 7, 2005), 5 pages.
“Designing Customs Peptides”, SIGMA Genosys, ://www.sigma-genosys.com/peptide—design.asp, (Dec. 16, 2004), 2 pages.
Abbott Cardiovascular Systems, Non Final Office Action dated Jun. 1, 2009 for U.S. Appl. No. 11/946,028.
Abbott Cardiovascular Systems, International search report and written opinion dated May 15, 2009 for PCT/US2008/012793, (May 15, 2009).
Berendsen, H. , “A glimpse of the holy grail?”, Science, vol. 282, www.sciencemag.org, (Oct. 1998), 642-643.
Bradley, et al., “Limits of cooperativity in a structurally modular protein: response of the notch ankyrin domain to analogous alanine substitutions in each repeat”, J. Mol. Biol., 324, (2002), 373-386.
Luck, et al., “Plasma protein adsorption on biodegradable microsheres consisting of poly(d,l-lactide-co-glycolide), poly(l-lactide) or ABA triblock copolymers containing poly(oxyethylene)—Influence of production method and polymer composition”, Journal of Controlled Release, Elsevier, vol. 55, No. 2-3, (Nov. 13, 1998), 107-120.
Ng, Pauline C., et al., “Predicting the effects of amino acid substitutions on protein function”, Annu. Rev. Genom. Human Genet., vol. 7, (1994), 61-80.
Ngo, J. T., et al., “Computational complexity, protein structure prediction, and the levinthal paradox”, The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser Boston, (1994), 491-495.
Prokop, et al., “Nanovehicular intracellular delivery systems”, Journal of Pharmaceutical Sciences, vol. 97, No. 9, (Sep. 2008), 3518-3590.
Rudinger, J., “Characteristics of the amino acides as components of a peptide hormone sequence”, Peptide Hormones, JA, Parsons Edition, University Park Press, (Jun. 1976), 1-7.
Schinzel, R., et al., “The phosphate recognition site ofEscherichia colimaltodextrin phosphorylase”, Federation of European Biochemical Societies, vol. 286, No. 1,2, (Jul. 1991), 125-128.
Voet, D., et al., “Abnormal Hemoglobins”, Biochemistry, Second Edition, Section 9-3, (1995), 235-241.
Aragane, K., et al., “ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits”, Journal of Lipid Research, 42, (2001), 480-488.
Batetta, B., et al., “Role of cholesterol ester pathway in the control of cell cycle in human aortic smooth muscle cells”, FASEB Journal, 17, (2003), 746-748.
Chang, T. Y., et al., “Catalysis of ACAT may be completed within the plane of membrane: a working hypothesis”, Journal of Lipid Research, 42, (2001), 1933-1938.
Datta, G., et al., “Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity”, Journal of Biological Chemistry, 279(24), (2004), 26509-26517.
Gupta, H., et al., “Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide”, Circulation Research, 97, (2005), 236-243.
Hartgerink, J. D., et al., “Peptide-amphiphile nanofibers: a versatile scaffold for the preparation of self-assembling materials”, PNAS, 99(8), (Apr. 2002), 5133-5138.
Hartgerink, J. D., et al., “Self-assembly and mineralization and peptide-amphiphile nanofibers”, Science, www.sciencemag.org, 294
Davalian Dariush
Hossainy Syed F. A.
Ludwig Florian
Murase Katsuyuki
Wan Jinping
Abbott Cardiovascular Systems Inc.
Blakely , Sokoloff, Taylor & Zafman LLP
Desai Anand
Shen Randy
LandOfFree
Sustained release of apo A-I mimetic peptides and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release of apo A-I mimetic peptides and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release of apo A-I mimetic peptides and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4281036